Travere Therapeutics Q1 2024 Adj EPS $(1.51) Misses $(0.99) Estimate, Sales $41.374M Miss $42.847M Estimate
Travere Therapeutics Q1 2024 Adj EPS $(1.51) Misses $(0.99) Estimate, Sales $41.374M Miss $42.847M Estimate
Travere Therapeutics 2024年第一季度調整後每股收益美元（1.51）未達到預期（0.99 美元），銷售額爲4137.4萬美元，低於4284.7萬美元的預期
Travere Therapeutics (NASDAQ:TVTX) reported quarterly losses of $(1.51) per share which missed the analyst consensus estimate of $(0.99) by 52.53 percent. This is a 64.13 percent decrease over losses of $(0.92) per share from the same period last year. The company reported quarterly sales of $41.374 million which missed the analyst consensus estimate of $42.847 million by 3.44 percent. This is a 33.95 percent increase over sales of $30.888 million the same period last year.
Travere Therapeutics（納斯達克股票代碼：TVTX）公佈的季度虧損爲每股1.51美元（1.51美元），比分析師普遍預期的0.99美元（0.99美元）低52.53％。與去年同期每股虧損0.92美元（0.92）相比，下降了64.13％。該公司公佈的季度銷售額爲4137.4萬美元，比分析師普遍預期的4284.7萬美元低3.44％。這比去年同期的3,0888萬美元的銷售額增長了33.95％。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。